Dr. Joseph G. Rogers

El Dr. Joseph G. Rogers, director del Instituto del Corazón de Texas de la Facultad de Medicina de Baylor, es cardiólogo y profesor adjunto de la División de Cardiología de la Universidad de Duke. Es un referente internacional y con numerosas publicaciones en el campo de la insuficiencia cardíaca, el trasplante cardíaco y la circulación asistida mecánicamente.

Mostrar biografía completa

El Dr. Rogers es un apasionado de las iniciativas de atención basadas en el valor, la prestación e implementación de la gestión de la atención y las estrategias de salud de la población. La investigación del Dr. Rogers se centra en los aspectos clínicos de la insuficiencia cardíaca avanzada, incluidos los tratamientos farmacológicos y eléctricos para la insuficiencia cardíaca sistólica, el uso de dispositivos mecánicos de asistencia circulatoria, el trasplante cardíaco y los cuidados paliativos.

Antes de unirse a The Texas Heart Institute como presidente y director ejecutivo, se desempeñó como director médico en el Sistema de Salud de la Universidad de Duke (DUHS) en Durham, Carolina del Norte, donde fue responsable de proporcionar dirección clínica y estratégica para las actividades de los médicos en todas sus entidades clínicas. .

El Dr. Rogers recibió su título de médico en la Facultad de Medicina de la Universidad de Nebraska en Omaha. Completó su formación de residencia en medicina interna en la Universidad de Nebraska y su beca de investigación en cardiología en la Universidad de Washington en St. Louis, Missouri. Se unió a la facultad de Duke en 2004 y ocupó varios puestos de liderazgo, incluido el de Director Médico Asociado para el crecimiento y la implementación estratégicos, presidente interino del Departamento de Medicina de la escuela y miembro de la Junta Directiva de Duke Connected Care, el sistema de salud Organización responsable del cuidado. También se desempeñó como enlace estratégico clave del sistema de salud para la Clínica de diagnóstico privado, la organización de práctica médica para los proveedores de Duke, donde defendió las innovaciones en seguridad y calidad en todo el sistema de salud.

Dr. Joseph G. Rogers
Director del Instituto del Corazón de Texas en la Facultad de Medicina de Baylor
Cátedra dotada O'Quinn/Willerson
El Instituto del Corazón de Texas
6770 Avenida Bertner, MC 3-116
Houston, TX 77030
Oficina: 832-355-9320 | Fax: 832-355-6810
Correo electrónico: jrogers@texasheart.org

Ver Publicaciones

Posiciones del Instituto del Corazón de Texas

Intereses

  • Insuficiencia cardíaca avanzada
  • Tratamientos farmacológicos y eléctricos de investigación para la insuficiencia cardíaca sistólica
  • Dispositivos mecánicos de asistencia circulatoria
  • Trasplante cardiaco
  • Cuidados paliativos en el tratamiento de la insuficiencia cardiaca

Educación

  • Escuela de Medicina:

    Universidad de Nebraska (Omaha)

  • Residencia:

    Universidad de Nebraska (Omaha)

  • Becas:

    Beca de investigación sobre enfermedades cardiovasculares, Universidad de Washington (St. Louis, Missouri)

Afiliaciones académicas y clínicas

Honores, premios y membresías

Publicaciones

4862227 7DBQSZ99 1 alternativas-a-la-experimentación-con-animales 10 datos desc Rogers 37270 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22NEEKYH88%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Raghuram%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRaghuram%2C%20A.%2C%20Sprung%2C%20K.%2C%20Coulter%2C%20S.%20et%20al.%20%282025%29.%20Shaping%20the%20Future%20of%20%26%23x201C%3BCardio-Kidney-Metabolic%26%23x201D%3B%20Health%3A%20Insights%20From%20The%20Texas%20Heart%20Institute%26%23x2019%3Bs%202024%20Cardiometabolic%20Syndrome%20Conference.%20%26lt%3Bi%26gt%3BTexas%20Heart%20Institute%20Journal%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B52%26lt%3B%5C%2Fi%26gt%3B%2C%20e248536.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-24-8536%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-24-8536%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Shaping%20the%20Future%20of%20%5Cu201cCardio-Kidney-Metabolic%5Cu201d%20Health%3A%20Insights%20From%20The%20Texas%20Heart%20Institute%27s%202024%20Cardiometabolic%20Syndrome%20Conference%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arjun%22%2C%22lastName%22%3A%22Raghuram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%22%2C%22lastName%22%3A%22Sprung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20At%20the%20Texas%20Heart%20Institute%26%23039%3Bs%202024%20Cardiometabolic%20Syndrome%20Conference%2C%20held%20on%20August%2023%2C%202024%2C%20experts%20from%20diverse%20academic%20fields%20spoke%20about%20novel%20initiatives%20for%20addressing%20the%20worsening%20projections%20for%20cardiometabolic%20syndrome.%20Four%20major%20areas%20in%20which%20innovation%20is%20ongoing%20were%20highlighted%3A%20technology%2C%20policy%2C%20population%20health%2C%20and%20lifestyle%20and%20behavioral%20modification.%20This%20article%20presents%20a%20brief%20contextualization%2C%20summary%2C%20and%20analysis%20of%20the%20novel%20initiatives%20being%20implemented%20in%20each%20of%20these%204%20areas%20to%20address%20cardiometabolic%20syndrome.%20Despite%20alarming%20projections%2C%20cardiometabolic%20syndrome%20presents%20a%20unique%20opportunity%20for%20innovators%20to%20drive%20change%20through%20collaborative%2C%20multidisciplinary%20efforts.%22%2C%22date%22%3A%222025%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-24-8536%22%2C%22ISSN%22%3A%221526-6702%2C%200730-2347%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fthij.kglmeridian.com%5C%2Fview%5C%2Fjournals%5C%2Fthij%5C%2F52%5C%2F1%5C%2Farticle-e248536.xml%22%2C%22collections%22%3A%5B%227DBQSZ99%22%5D%2C%22dateModified%22%3A%222025-02-06T23%3A08%3A48Z%22%7D%7D%2C%7B%22key%22%3A%229X227XLK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hussain%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHussain%2C%20A.%2C%20Ramsey%2C%20D.%2C%20Lee%2C%20M.%20et%20al.%20%282023%29.%20Utilization%20rates%20of%20SGLT2%20inhibitors%20among%20patients%20with%20type%202%20diabetes%2C%20heart%20failure%2C%20and%20atherosclerotic%20cardiovascular%20disease%3A%20Insights%20from%20the%20Department%20of%20Veterans%20Affairs.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900185%26%23x2013%3B3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.024%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.03.024%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Utilization%20rates%20of%20SGLT2%20inhibitors%20among%20patients%20with%20type%202%20diabetes%2C%20heart%20failure%2C%20and%20atherosclerotic%20cardiovascular%20disease%3A%20Insights%20from%20the%20Department%20of%20Veterans%20Affairs%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliza%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ramsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhruv%22%2C%22lastName%22%3A%22Mahtta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammad%20Shahzeb%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Nambi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christie%20M.%22%2C%22lastName%22%3A%22Ballantyne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20A.%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrienne%20D.%22%2C%22lastName%22%3A%22Walker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waleed%20T.%22%2C%22lastName%22%3A%22Kayani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javed%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leandro%22%2C%22lastName%22%3A%22Slipczuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Biykem%22%2C%22lastName%22%3A%22Bozkurt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sankar%20D.%22%2C%22lastName%22%3A%22Navaneethan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Multiple%20clinical%20trials%20have%20demonstrated%20significant%20cardiovascular%20benefit%20with%20use%20of%20sodium-glucose%20cotransporter-2%20%28SGLT2%29%20inhibitors%20in%20patients%20with%20type%202%20diabetes%20%28T2DM%29%20and%20heart%20failure%20%28HF%29%20irrespective%20of%20ejection%20fraction.%20There%20are%20limited%20data%20evaluating%20real-world%20prescription%20and%20practice%20patterns%20of%20SGLT2%20inhibitors.%5CnOBJECTIVES%3A%20The%20authors%20sought%20to%20assess%20utilization%20rates%20and%20facility-level%20variation%20in%20the%20use%20among%20patients%20with%20established%20atherosclerotic%20cardiovascular%20disease%20%28ASCVD%29%2C%20HF%2C%20and%20T2DM%20using%20data%20from%20the%20nationwide%20Veterans%20Affairs%20health%20care%20system.%5CnMETHODS%3A%20The%20authors%20included%20patients%20with%20established%20ASCVD%2C%20HF%2C%20and%20T2DM%20seen%20by%20a%20primary%20care%20provider%20between%20January%201%2C%202020%2C%20and%20December%2031%2C%202020.%20They%20assessed%20the%20use%20of%20SGLT2%20inhibitors%20and%20the%20facility-level%20variation%20in%20their%20use.%20Facility-level%20variation%20was%20computed%20using%20median%20rate%20ratios%2C%20a%20measure%20of%20likelihood%20that%202%5Cu00a0random%20facilities%20differ%20in%20use%20of%20SGLT2%20inhibitors.%5CnRESULTS%3A%20Among%20105%2C799%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%20across%20130%20Veterans%20Affairs%20facilities%2C%2014.6%25%20received%20SGLT2%20inhibitors.%20Patients%20receiving%20SGLT2%20inhibitors%20were%20younger%20men%20with%20higher%20hemoglobin%20A1c%20and%20estimated%20glomerular%20filtration%20rate%20and%20were%20more%20likely%20to%20have%20HF%20with%20reduced%20ejection%20fraction%20and%20ischemic%20heart%20disease.%20There%20was%20significant%20facility-level%20variation%20of%20SGLT2%20inhibitor%20use%2C%20with%20an%20adjusted%20median%20rate%20ratio%20of%201.55%20%2895%25%5Cu00a0CI%3A%201.46-1.64%29%2C%20indicating%20a%2055%25%20residual%20difference%20in%20SGLT2%20inhibitor%20use%20among%20similar%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%20receiving%20care%20at%202%20random%20facilities.%5CnCONCLUSIONS%3A%20Utilization%20rates%20of%20SGLT2%20inhibitors%20are%20low%20in%20patients%20with%20ASCVD%2C%20HF%2C%20and%20T2DM%2C%20with%20high%20residual%20facility-level%20variation.%20These%20findings%20suggest%20opportunities%20to%20optimize%20SGLT2%20inhibitor%20use%20to%20prevent%20future%20adverse%20cardiovascular%20events.%22%2C%22date%22%3A%222023-05-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.03.024%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SIH54GGA%22%2C%227DBQSZ99%22%2C%22GL8QP2FN%22%2C%22FCV4W3RS%22%2C%22NTAHPDUG%22%5D%2C%22dateModified%22%3A%222023-06-08T18%3A07%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22ZANSTJ68%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitra%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaitra%2C%20N.%20S.%2C%20Dugger%2C%20S.%20J.%2C%20Balachandran%2C%20I.%20C.%20et%20al.%20%282023%29.%20Impact%20of%20the%202018%20UNOS%20heart%20transplant%20policy%20changes%20on%20patient%26%23xA0%3Boutcomes.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900038%26%23x2013%3B0.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.01.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.01.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%202018%20UNOS%20heart%20transplant%20policy%20changes%20on%20patient%5Cu00a0outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%20S.%22%2C%22lastName%22%3A%22Maitra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20J.%22%2C%22lastName%22%3A%22Dugger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabel%20C.%22%2C%22lastName%22%3A%22Balachandran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prateeti%22%2C%22lastName%22%3A%22Khazanie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22In%202018%2C%20the%20United%20Network%20for%20Organ%20Sharing%20implemented%20a%206-tier%20allocation%20policy%20to%20replace%20the%20prior%203-tier%20system.%20Given%20increasing%20listings%20of%20critically%20ill%20candidates%20for%20heart%20transplantation%20and%20lengthening%20waitlist%20times%2C%20the%20new%20policy%20aimed%20to%20better%20stratify%20candidates%20by%20waitlist%20mortality%2C%20shorten%20waiting%20times%20for%20high%20priority%20candidates%2C%20add%20objective%20criteria%20for%20common%20cardiac%20conditions%2C%20and%20further%20broaden%20sharing%20of%20donor%20hearts.%20There%20have%20been%20significant%20shifts%20in%20cardiac%20transplantation%20practices%20and%20patient%20outcomes%20following%20the%20implementation%20of%20the%20new%5Cu00a0policy%2C%20including%20changes%20in%20listing%20practices%2C%20waitlist%20time%20and%20mortality%2C%20transplant%20donor%20characteristics%2C%20post-transplantation%20outcomes%2C%20and%20mechanical%20circulatory%20support%20use.%20This%20review%20aims%20to%20highlight%20emerging%20trends%20in%20United%20States%20heart%20transplantation%20practice%20and%20outcomes%20following%20the%20implementation%20of%20the%202018%20United%20Network%20for%20Organ%20Sharing%20heart%20allocation%20policy%20and%20to%20address%20areas%20for%20future%20modification.%22%2C%22date%22%3A%22Feb%2016%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.01.009%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229FBUJBMU%22%2C%224XZV96J9%22%2C%227DBQSZ99%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-14T14%3A35%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22UEPATAH5%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Civitello%20and%20Rogers%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCivitello%2C%20A.%20B.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282023%29.%20Toward%20a%20self-actuating%20continuous%20flow%20ventricular%20assist%20device%3A%20the%20pudding%20is%20in%20the%20proof.%20%26lt%3Bi%26gt%3BASAIO%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B69%26lt%3B%5C%2Fi%26gt%3B%2C%2059%26%23x2013%3B60.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001881%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FMAT.0000000000001881%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Toward%20a%20self-actuating%20continuous%20flow%20ventricular%20assist%20device%3A%20the%20pudding%20is%20in%20the%20proof%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jan%2001%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FMAT.0000000000001881%22%2C%22ISSN%22%3A%221538-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229FBUJBMU%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22TXW6RMW4%22%5D%2C%22dateModified%22%3A%222023-01-06T17%3A15%3A59Z%22%7D%7D%2C%7B%22key%22%3A%2282UUHA72%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wang%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWang%2C%20N.%2C%20Gray%2C%20Z.%2C%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20et%20al.%20%282023%29.%20Robot-assisted%20resection%20of%20tricuspid%20valve%20papillary%20fibroelastoma.%20%26lt%3Bi%26gt%3BAnnals%20of%20Thoracic%20Surgery%20Short%20Reports%26lt%3B%5C%2Fi%26gt%3B%2C%20S2772993123001791.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.atssr.2023.04.007%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.atssr.2023.04.007%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Robot-assisted%20resection%20of%20tricuspid%20valve%20papillary%20fibroelastoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%22%2C%22lastName%22%3A%22Gray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20K.%22%2C%22lastName%22%3A%22Liao%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%225%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.atssr.2023.04.007%22%2C%22ISSN%22%3A%2227729931%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2772993123001791%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%22C2VFJYPK%22%2C%22Q46ISS7S%22%5D%2C%22dateModified%22%3A%222023-07-21T19%3A10%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22R3YNCLJK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Felker%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFelker%2C%20G.%20M.%2C%20Buttrick%2C%20P.%2C%20Rosenzweig%2C%20A.%20et%20al.%20%282022%29.%20Heart%20Failure%20Strategically%20Focused%20Research%20Network%3A%20Summary%20of%20results%20and%20future%20directions.%20%26lt%3Bi%26gt%3BJ%20Am%20Heart%20Assoc%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B11%26lt%3B%5C%2Fi%26gt%3B%2C%20e025517.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.025517%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.025517%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Heart%20Failure%20Strategically%20Focused%20Research%20Network%3A%20Summary%20of%20results%20and%20future%20directions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20Michael%22%2C%22lastName%22%3A%22Felker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Buttrick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Rosenzweig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Dale%22%2C%22lastName%22%3A%22Abel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larry%20A.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Bristow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saumya%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%20D.%22%2C%22lastName%22%3A%22DeVore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavros%20G.%22%2C%22lastName%22%3A%22Drakos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20C.%22%2C%22lastName%22%3A%22Fang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%20E.%22%2C%22lastName%22%3A%22Freedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%20F.%22%2C%22lastName%22%3A%22Hernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dean%20Y.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20A.%22%2C%22lastName%22%3A%22McKinsey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Newton-Cheh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravi%20V.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svati%20H.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Stehlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%20H.%22%2C%22lastName%22%3A%22Selzman%22%7D%5D%2C%22abstractNote%22%3A%22Heart%20failure%20remains%20among%20the%20most%20common%20and%20morbid%20health%20conditions.%20The%20Heart%20Failure%20Strategically%20Focused%20Research%20Network%20%28HF%20SFRN%29%20was%20funded%20by%20the%20American%20Heart%20Association%20to%20facilitate%20collaborative%2C%20high-impact%20research%20in%20the%20field%20of%20heart%20failure%20across%20the%20domains%20of%20basic%2C%20clinical%2C%20and%20population%20research.%20The%20Network%20was%20also%20charged%20with%20developing%20training%20opportunities%20for%20young%20investigators.%20Four%20centers%20were%20funded%20in%202016%3A%20Duke%20University%2C%20University%20of%20Colorado%2C%20University%20of%20Utah%2C%20and%20Massachusetts%20General%20Hospital-University%20of%20Massachusetts.%20This%20report%20summarizes%20the%20aims%20of%20each%20center%20and%20major%20research%20accomplishments%2C%20as%20well%20as%20training%20outcomes%20from%20the%20HF%20SFRN.%22%2C%22date%22%3A%22Sept%2020%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.025517%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%228PULYTSK%22%2C%22C27MTI39%22%5D%2C%22dateModified%22%3A%222022-10-05T15%3A45%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22QNPYBRQJ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Golden%20and%20Rogers%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGolden%2C%20L.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282022%29.%20Heart%20failure%20drug%20therapy%3A%20New%20treatments%2C%20new%20guidelines.%20%26lt%3Bi%26gt%3BTex%20Heart%20Inst%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B49%26lt%3B%5C%2Fi%26gt%3B%2C%20e227920.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7920%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-22-7920%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Heart%20failure%20drug%20therapy%3A%20New%20treatments%2C%20new%20guidelines%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Golden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Sept%2001%2C%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-22-7920%22%2C%22ISSN%22%3A%221526-6702%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227PRCM4JP%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22X2D36SJL%22%2C%22MDTREPAF%22%5D%2C%22dateModified%22%3A%222022-11-04T15%3A28%3A31Z%22%7D%7D%2C%7B%22key%22%3A%2289MC2836%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cogswell%20and%20Rogers%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCogswell%2C%20R.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282022%29.%20Residual%20heart%20failure%20on%20mechanically%20assisted%20circulation%3A%20A%20call%20to%20action.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20482%26%23x2013%3B484.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.05.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.05.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Residual%20heart%20failure%20on%20mechanically%20assisted%20circulation%3A%20A%20call%20to%20action%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Cogswell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22July%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2022.05.002%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%228PULYTSK%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A42%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22QTYXGFMP%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Al%20Rifai%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAl%20Rifai%2C%20M.%2C%20Newby%2C%20L.%20K.%2C%20Nair%2C%20A.%20P.%20et%20al.%20%282022%29.%20SGLT-2%20inhibitors%20for%20patients%20with%20heart%20failure%3A%20what%20have%20we%20learned%20recently%3F%20%26lt%3Bi%26gt%3BCurr%20Atheroscler%20Rep%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11883-022-01038-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11883-022-01038-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22SGLT-2%20inhibitors%20for%20patients%20with%20heart%20failure%3A%20what%20have%20we%20learned%20recently%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Al%20Rifai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20Kristin%22%2C%22lastName%22%3A%22Newby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%20P.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arunima%22%2C%22lastName%22%3A%22Misra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Savitri%22%2C%22lastName%22%3A%22Fedson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20In%20this%20review%2C%20we%20discuss%20the%20mechanisms%20of%20action%20of%20sodium-glucose%20cotransporter-2%20inhibitors%20%28SGLT-2i%29%20and%20the%20purported%20protective%20effects%20for%20mitigating%20heart%20failure%20%28HF%29-related%20outcomes.%5CnRECENT%20FINDINGS%3A%20Major%20randomized%20clinical%20trials%20have%20demonstrated%20the%20cardiovascular%20safety%20and%20efficacy%20of%20SGLT-2i%20among%20patients%20without%20known%20HF%20and%20those%20with%20established%20HF%20with%20reduced%20ejection%20fraction%20or%20preserved%20ejection%20fraction%20%28HFrEF%20and%20HFpEF%20respectively%29.%20Recent%20HF%20guidelines%20have%20incorporated%20SGLT-2i%20in%20HF%20treatment%20algorithms.%20SGLT-2i%20have%20emerged%20as%20a%20novel%20treatment%20for%20both%20prevention%20of%20HF%20and%20reduction%20of%20cardiovascular%20morbidity%20and%20mortality%20among%20patients%20with%20existing%20HFrEF%20or%20HFpEF.%22%2C%22date%22%3A%22June%2002%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11883-022-01038-2%22%2C%22ISSN%22%3A%221534-6242%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22ZSY78DJL%22%5D%2C%22dateModified%22%3A%222022-07-06T19%3A09%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22Y6VPWZGE%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Shah%20and%20Rogers%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BShah%2C%20P.%20and%20%26lt%3Bstrong%26gt%3BRogers%26lt%3B%5C%2Fstrong%26gt%3B%2C%20J.%20G.%20%282022%29.%20Thrivival%3A%20Thriving%20and%20surviving%20for%20left%20ventricular%20assist%20device%20patients.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B10%26lt%3B%5C%2Fi%26gt%3B%2C%20333%26%23x2013%3B335.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.02.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2022.02.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Thrivival%3A%20Thriving%20and%20surviving%20for%20left%20ventricular%20assist%20device%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Palak%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2022.02.009%22%2C%22ISSN%22%3A%2222131779%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2213177922001767%22%2C%22collections%22%3A%5B%227DBQSZ99%22%2C%228PULYTSK%22%2C%22ZH6PLEMG%22%5D%2C%22dateModified%22%3A%222022-05-12T13%3A34%3A19Z%22%7D%7D%5D%7D
Raghuram, A., Sprung, K., Coulter, S. et al. (2025). Dar forma al futuro de la salud “cardio-renal-metabólica”: perspectivas de la Conferencia sobre el síndrome cardiometabólico de 2024 del Texas Heart Institute. Revista del Instituto del Corazón de Texas 52, E248536. https://doi.org/10.14503/THIJ-24-8536.
Hussain, A., Ramsey, D., Lee, M. et al. (2023). Tasas de utilización de inhibidores de SGLT2 entre pacientes con diabetes tipo 2, insuficiencia cardíaca y enfermedad cardiovascular aterosclerótica: conocimientos del Departamento de Asuntos de Veteranos. Insuficiencia cardíaca JACC, S2213-1779(23)00185–3. https://doi.org/10.1016/j.jchf.2023.03.024.
Maitra, NS, Dugger, SJ, Balachandran, IC et al. (2023). Impacto de los cambios en la política de trasplante de corazón de UNOS de 2018 en los resultados de los pacientes. Insuficiencia cardíaca JACC, S2213-1779(23)00038–0. https://doi.org/10.1016/j.jchf.2023.01.009.
Civitello, AB y Rogers, JG (2023). Hacia un dispositivo de asistencia ventricular de flujo continuo autoactuante: el pudín está en la prueba. ASAIO J. 69, 59-60. https://doi.org/10.1097/MAT.0000000000001881.
Wang, N., Gray, Z., Rogers, JG et al. (2023). Resección asistida por robot del fibroelastoma papilar de la válvula tricúspide. Anales de informes breves de cirugía torácica, S2772993123001791. https://doi.org/10.1016/j.atssr.2023.04.007.
Felker, GM, Buttrick, P., Rosenzweig, A. et al. (2022). Red de investigación estratégicamente enfocada en la insuficiencia cardíaca: resumen de resultados y direcciones futuras. Asociación J Am Heart 11, E025517. https://doi.org/10.1161/JAHA.122.025517.
Dorado, L. y Rogers, JG (2022). Terapia farmacológica para la insuficiencia cardíaca: nuevos tratamientos, nuevas pautas. Tex Corazón Inst J 49, E227920. https://doi.org/10.14503/THIJ-22-7920.
Cogswell, R. y Rogers, JG (2022). Insuficiencia cardíaca residual en circulación asistida mecánicamente: un llamado a la acción. Insuficiencia cardíaca JACC 10, 482-484. https://doi.org/10.1016/j.jchf.2022.05.002.
Al Rifai, M., Newby, LK, Nair, AP et al. (2022). Inhibidores de SGLT-2 para pacientes con insuficiencia cardíaca: ¿qué hemos aprendido recientemente? Representante de Curr Atheroscler. https://doi.org/10.1007/s11883-022-01038-2.
Shah, P. y Rogers, JG (2022). Thrivival: prosperar y sobrevivir para los pacientes con dispositivos de asistencia ventricular izquierda. Insuficiencia cardíaca JACC 10, 333-335. https://doi.org/10.1016/j.jchf.2022.02.009.

Noticias Recientes

Ver Todas

Liderando con experiencia y compasión: La generación de junio de 2025 de la Escuela de Perfusión del Instituto del Corazón de Texas

La Escuela de Tecnología de Perfusión del Texas Heart Institute (THI) incorporó con orgullo ocho nuevos exalumnos talentosos a los más de 1000...

Read more

Presentando el futuro de la medicina cardiovascular: el Programa de Becas del Instituto del Corazón de Texas celebra a los graduados de cardiología de 2025

En la noche del 6 de junio de 2025, el Texas Heart Institute en Baylor College of Medicine (THI) celebró los logros...

Read more
tecnología usable

Dando forma al futuro de la salud metabólica: perspectivas del Texas Heart Institute

El 23 de agosto de 2024, el Texas Heart Institute organizó la Conferencia sobre el síndrome cardiometabólico: una crisis de salud poblacional, que reunió a...

Read more
Fragmentos de código PHP Desarrollado por: XYZScripts.com